Julie has over 25 years of experience in Equity Research, covering both UK and continental European companies across a wide range of healthcare subsectors including healthcare services, biotechnology, medical devices and digital health.
She joined Panmure Gordon in November 2015 from Canaccord Genuity and previously spent seven years at Piper Jaffray.
Julie was No.1 Extel rated 2018 and rated Analyst of the Year 2022 by the Small Cap Network Awards. She is also a panel member for NIHR i4i (invention for innovation), assessing early-stage medical technologies.
Julie has a PhD in Microbiology from the University of Kent.
